Pemphigus autoimmunity: Hypotheses and realities

Autoimmunity

Volumn 45, Issue 1, 2012, Pages 7-35

  Grando, Sergei A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptolysis; Autoantibody; Autoantigen; Pemphigus foliaceus; Pemphigus vulgaris; Prednisone

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CALMODULIN; CELL ADHESION MOLECULE; CHOLINERGIC RECEPTOR; COLLAGEN TYPE 17; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; DESMOCOLLIN; DESMOGLEIN; DESMOGLEIN 1; DESMOGLEIN 2; DESMOGLEIN 3; DESMOPLAKIN; DESMOSOMAL CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; IMMUNOGLOBULIN G ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE ANTIGEN; MEMBRANE RECEPTOR; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE C; PLAKOGLOBIN; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SERINE PROTEINASE; STRESS ACTIVATED PROTEIN KINASE; UVOMORULIN;

ACANTHOLYSIS; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BASAL CELL; CELL DEATH; CELL MEMBRANE; CYTOLYSIS; DESMOSOME; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; KERATINOCYTE; NONHUMAN; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; REMISSION;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; IMMUNOMODULATION; KERATINOCYTES; PEMPHIGUS;

EID: 84856457013     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.606444     Document Type: Article

References (351)

1. Grando SA, Bystryn JC, Chernyavsky AI, Frusic-Zlotkin M, Gniadecki R, Lotti R, Milner Y, Pittelkow MR, Pincelli C. Apoptolysis: A novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp Dermatol 2009;18:764-770.
2. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of Pemphigus vulgaris. J Am Acad Dermatol 1996;34:645-652. (Pubitemid 26098015)
3. Ahmed AR, Moy R. Death in Pemphigus. J Am Acad Dermatol 1982;7:221-228. (Pubitemid 12092372)
4. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: A 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976;112:962-970.
5. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, 3rd, Ratrie H, Mutasim D, Ariss-Abdo L, Labib RS. Paraneoplastic Pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323:1729-1735.
6. Kaplan RP, Callen JP. Pemphigus associated diseases and induced Pemphigus. Clin Dermatol 1983;1:42-71.
7. Armin A, Nadimi H, Robinson J. Pemphigus vulgaris and malignancy. Int J Oral Surg 1985;14:376-380. (Pubitemid 15227160)
8. Younus J, Ahmed AR. The relationship of Pemphigus to neoplasia. J Am Acad Dermatol 1990;23:498-502. (Pubitemid 20281688)
9. Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic Pemphigus. J Am Acad Dermatol 2001;44:593-598. (Pubitemid 32249513)
10. Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS,Webber RJ, PittelkowMR, Lynch PJ, Grando SA. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: A reappraisal of paraneoplastic Pemphigus. Arch Dermatol 2001;137:193-206. (Pubitemid 32163671)
11. Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, Anhalt GJ. The mechanism of respiratory failure in paraneoplastic Pemphigus.NEngl J Med 1999;340: 1406-1410. (Pubitemid 29205404)
12. Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: Twenty years after. Int J Dermatol 2011;50(8):905-914.
13. Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006;39:617-630. (Pubitemid 44768931)
14. Beutner E, Jordon R. Demonstration of skin antibodies in sera of Pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964;117: 505-510.
15. Beutner EH, Prigenzi LS, Hale W, Leme Cde A, Bier OG. Immunofluorescent studies of autoantibodies to intercellular areas of epithelia in Brazilian Pemphigus foliaceus. Proc Soc Exp Biol Med 1968;127:81-86.
16. Stanley JR, Yaar M, Hawley-Nelson P, Katz SI. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest 1982;70: 281-288. (Pubitemid 12042626)
17. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in Pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869-877. (Pubitemid 121001501)
18. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce Pemphigus vulgaris-like lesions. J Clin Invest 2000;106:1467-1479. (Pubitemid 32038585)
19. Ablin RJ, Bronson P, Beutner EH. Immunochemical characterization of epithelial antigen(s) reactive with Pemphigus-like antibodies of rabbit and human Pemphigus autoantibodies. J Hyg Epidemiol Microbiol Immunol 1969; 13:321-329.
20. Shu SY, Beutner EH. Isolation and characterization of antigens reactive with Pemphigus antibodies. J Invest Dermatol 1973;61:270-276.
21. Miyagawa S, Hojo T, Ishii H, Yoshioka J, Sakamoto K. Isolation and characterization of soluble epidermal antigens reactive with Pemphigus antibodies. Acta Derm Venereol 1977;57:7-13. (Pubitemid 8018528)
22. Calvanico NJ, Swartz SJ. A non-desmoglein component of bovine epidermis reactive with Pemphigus foliaceus sera. J Autoimmun 1994;7:231-242. (Pubitemid 24182440)
23. Calvanico NJ, Martins CR, Diaz LA. Characterization of Pemphigus foliaceus antigen from human epidermis. J Invest Dermatol 1991;96:815-821.
24. Diaz LA, Patel H, Calvanico NJ. Isolation of Pemphigus antigen from human saliva. J Immunol 1980;124:760-765. (Pubitemid 10135317)
25. Diaz LA, Sampaio SA, Martins CR, Rivitti EA, Macca ML, Roscoe JT, et al. An autoantibody in Pemphigus serum, specific for the 59kD keratin, selectively binds the surface of keratinocytes: Evidence for an extracellular keratin domain. J Invest Dermatol 1987;89:287-295. (Pubitemid 17126582)
26. Murahata RI, Ahmed AR. Partial purification and characterization of Pemphigus-like antigens in urine. Arch Derm Res 1983;275:118-123. (Pubitemid 13122520)
27. Peterson LL, Wuepper KD. Isolation and purification of a Pemphigus vulgaris antigen from human epidermis. J Clin Invest 1984;73:1113-1120. (Pubitemid 14132842)
28. Acosta E, Ivanyi L. Identification of Pemphigus-like antigens expressed by SCaBER cells. Br J Dermatol 1985;112: 157-164. (Pubitemid 15165806)
29. Stanley JR, Koulu L, Thivolet C. Distinction between epidermal antigens binding Pemphigus vulgaris and Pemphigus foliaceus autoantibodies. J Clin Invest 1984;74:313-320. (Pubitemid 14053977)
30. Gilbert D, Joly P, Jouen F, Thibout A, Delpech A, Thomine E, Lauret P, Tron F. Production of a human monoclonal antiepithelial cell surface antibody derived from a patient with Pemphigus vulgaris. J Autoimmun 1992;5:173-182.
31. + signalling. Israel J Med Sci 1995;31:42-48.
32. Kiss M, Husz S, Molnar K, Dobozy A. Identification of different circulating autoantibodies in patients with bullous Pemphigoid and Pemphigus vulgaris by means of immunoblotting. Acta Microbiol Immunol Hung 1996;43:115-123. (Pubitemid 126417517)
33. Ding X, Aoki V, Mascaro JM, Jr, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) Pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997;109:592-596. (Pubitemid 27433607)
34. Joly P, Gilbert D, Thomine E, Zitouni M, Ghohestani R, Delpech A, Lauret P, Tron F. Identification of a new antibody population directed against a desmosomal plaque antigen in Pemphigus vulgaris and Pemphigus foliaceus. J Invest Dermatol 1997;108:469-475. (Pubitemid 27148283)
35. Eyre RW, Stanley JR. Identification of Pemphigus vulgaris antigen extracted from normal human epidermis and comparison with Pemphigus foliaceus antigen. J Clin Invest 1988;81:807-812. (Pubitemid 18079729)
36. Nguyen VT, Ndoye A, Grando SA. Novel human a9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol 2000;157:1377-1391.
37. Marchenko S, Chernyavsky AI, Arredondo J, Gindi V, Grando SA. Antimitochondrial autoantibodies in Pemphigus vulgaris: A missing link in disease pathophysiology. J Biol Chem 2010;285:3695-3704.
38. Cirillo N, Gombos F, Lanza A. Pemphigus vulgaris immunoglobulin G can recognize a 130 000 MW antigen other than desmoglein 3 on peripheral blood mononuclear cell surface. Immunology 2007;121:377-382. (Pubitemid 46817359)
39. Mejri K, Abida O, Kallel-Sellami M, Haddouk S, Laadhar L, Zarraa I, Ben Ayed M, Zitouni M, Mokni M, Lahmar H, Fezaa B, Turki H, Tron F, Masmoudi H, Makni S. Spectrum of autoantibodies other than anti-desmoglein in Pemphigus patients. J Eur Acad Dermatol Venereol 2010;25(7): 774-781.
40. Stanley JR, Koulu L, Klaus-Kovtun V, Steinberg MS. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in Pemphigus foliaceus. J Immunol 1986; 136:1227-1230. (Pubitemid 16156220)
41. Kurzen H, Brenner S. Significance of autoimmunity to nondesmoglein targets in Pemphigus. Autoimmunity 2006;39: 549-556. (Pubitemid 44768923)
42. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in Pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-468. (Pubitemid 29094045)
43. Chen J, Den Z, Koch PJ. Loss of desmocollin 3 in mice leads to epidermal blistering. J Cell Sci 2008;121:2844-2849.
44. Amagai M, Karpati S, Klaus-Kovtun V, Udey MC, Stanley JR. Extracellular domain of Pemphigus vulgaris antigen (Desmoglein 3) mediates weak homophilic adhesion. J Invest Dermatol 1994;102:402-408. (Pubitemid 24117176)
45. Green KJ, Simpson CL. Desmosomes: New perspectives on a classic. J Invest Dermatol 2007;127:2499-2515. (Pubitemid 47585074)
46. Desai BV, Harmon RM, Green KJ. Desmosomes at a glance. J Cell Sci 2009;122:4401-4407.
47. Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein versus non-desmoglein signaling in Pemphigus acantholysis: Characterization of novel signaling pathways downstream of Pemphigus vulgaris antigens. J Biol Chem 2007;282:13804-13812. (Pubitemid 47100562)
48. Nguyen VT, Lee TX, Ndoye A, Shultz LD, Pittelkow MR, Dahl MV, Lynch PJ, Grando SA. The pathophysiological significance of non-desmoglein targets of Pemphigus autoimmunity. Pemphigus vulgaris and foliaceus patients develop antibodies against keratinocyte cholinergic receptors. Arch Dermatol 1998;134:971-980.
49. Kalantari-Dehaghi M, Molina DM, Farhadieh M, Morrow WJ, Liang X, Felgner PL, Grando SA. New targets of Pemphigus vulgaris antibodies identified by protein array technology. Exp Dermatol 2011;20:154-156.
50. Kalantari-Dehaghi M, Anhalt G, Camilleri M, Leiferman KM, Marchenko S, Pittelkow M, Zone JJ, Grando SA. Pemphigus vulgaris antibodies target PERP and several other keratinocyte membrane and mitochondrial proteins. J Invest Dermatol 2011;131(Suppl. 1):S11.
51. Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT, Mills AA, Attardi LD. Perp is a p63-regulated gene essential for epithelial integrity. Cell 2005; 120:843-856. (Pubitemid 40568801)
52. Bektas M, Rubenstein DS. Perp and Pemphigus: A disease of desmosome destabilization. J Invest Dermatol 2009;129: 1606-1608.
53. Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T, Attardi LD. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 2003;13:1985-1990. (Pubitemid 37425209)
54. Davies L, Gray D, Spiller D, White MR, Damato B, Grierson I, Paraoan L. P53 apoptosis mediator PERP: Localization, function and caspase activation in uveal melanoma. J Cell Mol Med 2009;13:1995-2007.
55. Grando SA. Cholinergic control of epidermal cohesion in norm and pathology. Exp Dermatol 2006;15:265-282. (Pubitemid 43349068)
56. Grando SA, Kurzen H. Cholinergic control of keratinocyte cohesion. In: Cirillo N, Lanza A, Gombo F, editors. Pathophysiology of the desmosome. Research Signpost, Managing Editor Dr. S.G. Pandalai, Trivandrum, Kerala, India. 2009. p 104.
57. Grando SA, George PM, Dahl MV, Conti-Tronconi BM. Antibody against keratinocyte nicotinic acetylcholine receptor in patient with coexistent Pemphigus foliaceus, myasthenia gravis and thymoma. J Invest Dermatol 1994;102:609, (Abstr.).
58. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 1997;40: 1374-1382. (Pubitemid 27430946)
59. Lindstrom J. Autoimmune diseases involving nicotinic receptors. J Neurobiol 2002;53:656-665. (Pubitemid 35375594)
60. Kalantari M, Molina DM, Farhadieh M, Vigil A, Morrow WJ, Liang X, Felgner PL, Grando SA. Partial evaluation of Pemphigus vulgaris autoantibody profile using the protein array technology. J Invest Dermatol 2010;130(Suppl. 1):S21.
61. Patel M, Furstenberg G, Hazelton J, Tiagi S, Seiffert-Sinha K, Haab BB, Robinson WH, Sinha AA. Development of protein microarrays to investigate autoantibody profiles in Pemphigus vul-garis (abstr. #111). J Invest Dermatol 2010; 130(Suppl. 1):s19.
62. Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin-a novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000;275:29466-29476. (Pubitemid 32043822)
63. Bastian BC, Nuss B, Romisch J, Kraus M, Brocker EB. Autoantibodies to annexins: A diagnostic marker for cutaneous disorders? J Dermatol Sci 1994;8:194-202. (Pubitemid 24353986)
64. Abreu Velez AM, Yi H, Gao W, Smoller BR, Grossniklaus HE, Howard MS. Antibodies to pilosebaceous units along their neurovascular supply routes in a new variant of endemic Pemphigus foliaceus in Colombia, South America. Eur J Dermatol 2011;21(3):371-375.
65. Echigo T, Hasegawa M, Inaoki M, Yamazaki M, Sato S, Takehara K. Antiphospholipid antibodies in patients with autoimmune blistering disease. J Am Acad Dermatol 2007; 57:397-400. (Pubitemid 47239130)
66. Blondin DA, Zhang Z, Shideler KK, Hou H, Fritzler MJ, Mydlarski PR. Prevalence of non-organ-specific autoantibodies in patients with Pemphigus vulgaris. J Cutan Med Surg 2009;13:82-87.
67. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of Pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-926.
68. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of Pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994;94:59-67. (Pubitemid 24218077)
69. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in Pemphigus foliaceus. J Invest Dermatol 1995; 104:895-901.
70. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (Pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic Pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998;102:775-782. (Pubitemid 28399610)
71. Moller NP. Fc-mediated immune precipitation. I. A new role of the Fc-portion of IgG. Immunology 1979;38:631-640. (Pubitemid 10131909)
72. Moller NP, Steensgaard J. Fc-mediated immune precipitation. II. Analysis of precipitating immune complexes by rate-zonal ultracentrifugation. Immunology 1979;38: 641-648. (Pubitemid 10131910)
73. Kolenko P, Dohnalek J, Duskova J, Skalova T, Collard R, Hasek J. New insights into intra-and intermolecular interactions of immunoglobulins: Crystal structure of mouse IgG2b-Fc at 2.1-A resolution. Immunology 2009; 126:378-385.
74. Kaithamana S, Fan JL, Memar O, Li K, Jutto J, Seetharamaiah GS, Prabhakar BS. Relevance of differential immunogenicity of human and mouse recombinant desmoglein-3 for the induction of acantholytic autoantibodies in mice. Clin Exp Immunol 2003;132:16-23. (Pubitemid 36418901)
75. Angelini G, Bonamonte D, Lin MS, Lucchese A, Mittelman A, Serpico R, Simone S, Sinha AA, Kanduc D. Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J Exp Ther Oncol 2005;5:1-7. (Pubitemid 41076984)
76. Nishimura H, Strominger JL. Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. Proc Natl Acad Sci USA 2006;103:3292-3297. (Pubitemid 43346463)
77. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawam T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for Pemphigus. J Clin Invest 2000;105:625-631. (Pubitemid 30146509)
78. Aoki-Ota M, Tsunoda K, Ota T, Iwasaki T, Koyasu S, Amagai M, Nishikawa T. A mouse model of Pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br J Dermatol 2004;151: 346-354. (Pubitemid 39215148)
79. Amagai M. Pemphigus vulgaris and its active disease mouse model. Curr Dir Autoimmun 2008;10:167-181.
80. Holm TL, Markholst H. Confirmation of a disease model of Pemphigus vulgaris: Characterization and correlation between disease parameters in 90 mice. Exp Dermatol 2010;19:e158-e165.
81. Ishii K, Harada R, Matsuo I, Shirakata Y, Hashimoto K, Amagai M. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in Pemphigus vulgaris. J Invest Dermatol 2005;124:939-946. (Pubitemid 40629094)
82. Bhol KC, Ahmed AR. Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from Pemphigus vulgaris patient. Autoimmunity 2002;35:87-91. (Pubitemid 34678726)
83. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, Tsunoda K, Amagai M, Stanley JR, Siegel DL. Genetic and functional characterization of human Pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005;115:888-899. (Pubitemid 40489393)
84. Shimizu A, Ishiko A, Ota T, Tsunoda K, Amagai M, Nishikawa T. IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a Pemphigus mouse model. J Invest Dermatol 2004;122: 1145-1153. (Pubitemid 38651089)
85. Shimizu A, Ishiko A, Ota T, Saito H, Oka H, Tsunoda K, Amagai M, Nishikawa T. In vivo ultrastructural localization of the desmoglein 3 adhesive interface to the desmosome mid-line. J Invest Dermatol 2005;124:984-989. (Pubitemid 40629100)
86. Lever WF. Pemphigus. Medicine 1953;32:2-123.
87. Wilgram GF, Caulfield JB, Lever WF. An electron microscopic study of acantholysis in Pemphigus vulgaris. J Invest Dermatol 1961;36:373-382.
88. Hu CH, Michel B, Schiltz JR. Epidermal acantholysis induced in vitro by Pemphigus autoantibody. An ultrastructural study. Am J Pathol 1978;90:345-361. (Pubitemid 8282650)
89. Barlow Y, Wray D. Ultrastructural alterations associated with in vivo and in vitro bound Pemphigus antibodies in cultured oral epithelial cells. J Oral Pathol Med 1991;20:241-244.
90. Diercks GF, Pas HH, Jonkman MF. The ultrastructure of acantholysis in Pemphigus vulgaris. Br J Dermatol 2009;160: 450-474.
91. Lambert LL, Spriet E, Vandewiele A, Naeyaert J. Desmoglein 1 and 3 IgG auto-antibody titers do not correlate with Pemphigus disease activity in a prospective study. J Invest Dermatol 2006;126(Suppl. 1):11, (Abstract 65).
92. Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of Pemphigus. Arch Dermatol 2009;145: 529-535.
93. Akman A, Uzun S, Alpsoy E. Immunopathologic features of Pemphigus in the east Mediterranean region of Turkey: A prospective study. Skinmed 2010;8:12-16.
94. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of Pemphigus. Br J Dermatol 2005;153:620-625. (Pubitemid 41248223)
95. Kwon EJ, Yamagami J, Nishikawa T, Amagai M. Antidesmoglein IgG autoantibodies in patients with Pemphigus in remission. J Eur Acad Dermatol Venereol 2008;22: 1070-1075.
96. Belloni-Fortina A, Faggion D, Pigozzi B, Peserico A, Bordignon M, Baldo V, Alaibac M. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with Pemphigus vulgaris: Correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol 2009;2009:187864.
97. Brandsen R, Frusic-Zlotkin M, Lyubimov H, Yunes F, Michel B, Tamir A, Milner Y, Brenner S. Circulating Pemphigus IgG in families of patients with Pemphigus: Comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. J Am Acad Dermatol 1997;36:44-52. (Pubitemid 27043873)
98. Warren SJ, Lin MS, Giudice GJ, Hoffmann RG, Hans-Filho G, Aoki V, Rivitti EA, Santos V, Diaz LA. The prevalence of antibodies against desmoglein 1 in endemic Pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. N Engl J Med 2000;343:23-30. (Pubitemid 30447988)
99. Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, Milner Y. The distribution of Pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in Pemphigus patients and their firstdegree relatives. Br J Dermatol 2000;143:337-342. (Pubitemid 30650402)
100. Torzecka JD, Narbutt J, Sysa-Jedrzejowska A, Waszczykowska E, Lukamowicz J, Pas HH. Detection of Pemphigus autoantibodies by IIF and ELISA tests in patients with Pemphigus vulgaris and foliaceus and in healthy relatives. Med Sci Monit 2003;9:CR528-CR533. (Pubitemid 38009853)
101. Torzecka JD, Wozniak K, Kowalewski C, Waszczykowska E, Sysa-Jedrzejowska A, Pas HH, Narbutt J. Circulating Pemphigus autoantibodies in healthy relatives of Pemphigus patients: Coincidental phenomenon with a risk of disease development? Arch Dermatol Res 2007;299:239-243. (Pubitemid 47222922)
102. Hilario-Vargas J, Dasher DA, Li N, Aoki V, Hans-Filho G, Dos Santos V, Qaqish BF, Rivitti EA, Diaz LA. Prevalence of anti-desmoglein-3 antibodies in endemic regions of Fogo Selvagem in Brazil. J Invest Dermatol 2006;126:2044-2048.
103. Ortega Loayza AG, Ramos W, Elgart G, Bouman P, Jimenez G, Avila J, Rojas I, Vilcarromero M, Hurtado J, Lindo G, Galarza C. Antibodies against desmoglein 1 in healthy subjects in endemic and nonendemic areas of Pemphigus foliaceus (fogo selvagem) in Peru. Int J Dermatol 2006;45: 538-542.
104. Diaz LA, Arteaga LA, Hilario-Vargas J, Valenzuela JG, Li N, Warren S, Aoki V, Hans-Filho G, Eaton D, dos Santos V, Nutman TB, de Mayolo AA, Qaqish BF, Sampaio SA, Rivitti EA. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. J Invest Dermatol 2004;123: 1045-1051. (Pubitemid 39586824)
105. Yoshimura T, Seishima M, Nakashima K, Yasuhara Y, Adachi S, Kawaguchi M, Minoura N, Nakao T, Kobayashi J, Yamazaki F. Increased antibody levels to desmogleins 1 and 3 after administration of carbamazepine. Clin Exp Dermatol 2001;26:441-445. (Pubitemid 32863102)
106. Gallo R, Massone C, Parodi A, Guarrera M. Allergic contact dermatitis from thiurams with Pemphigus-like autoantibodies. Contact Dermatitis 2002;46:364-365. (Pubitemid 35007105)
107. Cozzani E, Rosa GM, Drosera M, Intra C, Barsotti A, Parodi A. ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells. Arch Dermatol Res 2010;303(5):327-332.
108. Khandpur S, Sharma VK, Sharma A, Pathria G, Satyam A. Comparison of enzyme-linked immunosorbent assay test with immunoblot assay in the diagnosis of Pemphigus in Indian patients. Indian J Dermatol Venereol Leprol 2010;76: 27-32.
109. Empinotti JC, Aoki V, Filgueira A, Sampaio SA, Rivitti EA, Sanches JA, Jr, Li N, Hilario-Vargas J, Diaz LA. Clinical and serological follow-up studies of endemic Pemphigus foliaceus (fogo selvagem) in Western Parana, Brazil (2001-2002). Br J Dermatol 2006;155:446-450. (Pubitemid 44050582)
110. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in Pemphigus vulgaris. Dermatology 1994;189(Suppl 1):85-89. (Pubitemid 24141436)
111. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in Pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci USA 1995;92:5239-5243.
112. Ayatollahi M, Joubeh S, Mortazavi H, Jefferis R, Ghaderi A. IgG4 as the predominant autoantibody in sera from patients with active state of Pemphigus vulgaris. J Eur Acad Dermatol Venereol 2004;18:241-242. (Pubitemid 38379924)
113. Nagel A, Lang A, Engel D, Podstawa E, Hunzelmann N, de Pita O, Borradori L, Uter W, Hertl M. Clinical activity of Pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010;134:320-330.
114. Mentink LF, de Jong MC, Kloosterhuis GJ, Zuiderveen J, Jonkman MF, Pas HH. Coexistence of IgA antibodies to desmogleins 1 and 3 in Pemphigus vulgaris, Pemphigus foliaceus and paraneoplastic Pemphigus. Br J Dermatol 2007; 156:635-641. (Pubitemid 46452350)
115. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of Pemphigus is defined by the antidesmoglein autoantibody profile. J Am Acad Dermatol 1999; 40:167-170. (Pubitemid 29072792)
116. Arteaga LA, Prisayanh PS, Warren SJ, Liu Z, Diaz LA, Lin MS. A subset of Pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. J Invest Dermatol 2002;118:806-811. (Pubitemid 34526542)
117. Cunha PR, Bystryn JC, Medeiros EP, de Oliveira JR. Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic Pemphigus foliaceus (Fogo Selvagem). Int J Dermatol 2006;45: 914-918. (Pubitemid 44149427)
118. Zagorodniuk I, Weltfriend S, Shtruminger L, Sprecher E, Kogan O, Pollack S, Bergman R. A comparison of antidesmoglein antibodies and indirect immunofluorescence in the serodiagnosis of Pemphigus vulgaris. Int J Dermatol 2005;44:541-544. (Pubitemid 40960113)
119. Sharma VK, Prasad HR, Khandpur S, Kumar A. Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with Pemphigus vulgaris. Int J Dermatol 2006;45:518-522.
120. Grando SA, Laquer VT, Le HM. Sirolimus for acute Pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection. J Am Acad Dermatol 2011;65(3):684-686.
121. Amagai M, Ahmed AR, Kitajima Y, Bystryn JC, Milner Y, Gniadecki R, Hertl M, Pincelli C, Fridkis-Hareli M, Aoyama Y, Frusic-Zlotkin M, Muller E, David M, Mimouni D, Vind-Kezunovic D, Michel B, Mahoney M, Grando S. Are desmoglein autoantibodies essential for the immunopathogenesis of Pemphigus vulgaris, or just "witnesses of disease"? Exp Dermatol 2006;15:815-831.
122. Ohata Y, Amagai M, Ishii K, HashimotoT. Immunoreactivity against intracellular domains of desmogleins in Pemphigus. J Dermatol Sci 2001;25:64-71. (Pubitemid 32012648)
123. Lanza A, Femiano F, De Rosa A, Cammarota M, Lanza M, Cirillo N. The N-terminal fraction of desmoglein 3 encompassing its immunodominant domain is present in human serum: Implications for Pemphigus vulgaris autoimmunity. Int J Immunopathol Pharmacol 2006;19: 399-407. (Pubitemid 44181962)
124. Dmochowski M, Hashimoto T, Garrod DR, Nishikawa T. Desmocollins I and II are recognized by certain sera from patients with various types of Pemphigus particularly Brazilian Pemphigus foliaceus. J Invest Dermatol 1993;100: 380-384. (Pubitemid 23105200)
125. Dmochowski M, Hashimoto T, Chidgey MAJ, Yue KKM, Wilkinson RW, Nishikawa T, Garrod DR. Demonstration of antibodies to bovine desmocollin isoforms in certain Pemphigus sera. Br J Dermatol 1995;133:519-525.
126. Hisamatsu Y, Amagai M, Garrod DR, Kanzaki T, Hashimoto T. The detection of IgG and IgA autoantibodies to desmocollins 1-3 by enzyme-linked immunosorbent assays using baculovirus-expressed proteins, in atypical Pemphigus but not in typical Pemphigus. Br J Dermatol 2004;151: 73-83. (Pubitemid 39061282)
127. Muller R, Heber B, Hashimoto T, Messer G, Mullegger R, Niedermeier A, Hertl M. Autoantibodies against desmocollins in European patients with Pemphigus. Clin Exp Dermatol 2009;34:898-903.
128. Spindler V, Heupel WM, Efthymiadis A, Schmidt E, Eming R, Rankl C, Hinterdorfer P, Muller T, Drenckhahn D, Waschke J. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in Pemphigus. J Biol Chem 2009;284:30556-30564.
129. Mao X, Nagler AR, Farber SA, Choi EJ, Jackson LH, Leiferman KM, Ishii N, Hashimoto T, Amagai M, Zone JJ, Payne AS. Autoimmunity to desmocollin 3 in Pemphigus vulgaris. Am J Pathol 2010;177:2724-2730.
130. Grando SA, Dahl MV. Activation of keratinocyte muscarinic acetylcholine receptors reverses Pemphigus acantholysis. J Eur Acad Dermatol Venereol 1993;2:72-86. (Pubitemid 23178422)
131. Grando SA, Horton RM, Pereira EFR, Diethelm-Okita BM, George PM, Albuquerque EX, Conti-Fine BM. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol 1995; 105:774-781. (Pubitemid 26006352)
132. Nguyen VT, Chernyavsky AI, Arredondo J, Bercovich D, Orr-Urtreger A, Vetter DE, Wess J, Beaudet AL, Kitajima Y, Grando SA. Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. Exp Cell Res 2004;294:534-549. (Pubitemid 38326750)
133. Kurzen H, Henrich C, Booken D, Poenitz N, Gratchev A, Klemke CD, Engstner M, Goerdt S, Maas-Szabowski N. Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol 2006;126:2458-2472. (Pubitemid 44582268)
134. Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in Pemphigus. Dermatology 2000;201:290-295. (Pubitemid 32037553)
135. Dick SE, Werth VP. Pemphigus: A treatment update. Autoimmunity 2006;39:591-600.
136. Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl 2001;235:3-15. (Pubitemid 33044511)
137. Tron F, Gilbert D, Joly P, Mouquet H, Drouot L, Ayed MB, Sellami M, Masmoudi H, Makni S. Immunogenetics of Pemphigus: An update. Autoimmunity 2006;39:531-540.
138. Saha M, Harman K, Mortimer NJ, Binda V, Black MM, Kondeatis E, Vaughan R, Groves RW. Pemphigus vulgaris in White Europeans is linked with HLA Class II allele HLA DRB1*1454 but not DRB1*1401. J Invest Dermatol 2010; 130:311-314.
139. Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA, Yunis EJ. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with Pemphigus vulgaris. Proc Natl Acad Sci USA 1991;88:5056-5060. (Pubitemid 21914682)
140. Niizeki H, Inoko H, Narimatsu H, Takata H, Sonoda A, Tadakuma T, Ando A, Tsuji K, Hashimoto T, Nishikawa T. HLA class II antigens are associated with Japanese Pemphigus patients. Hum Immunol 1991;31:246-250.
141. Niizeki H, Inoko H, Mizuki N, Inamoto N, Watababe K, Hashimoto T, Nishikawa T. HLA-DQA1, -DQB1 and -DRB1 genotyping in Japanese Pemphigus vulgaris patients by the PCR-RFLP method. Tissue Antigens 1994; 44:248-251. (Pubitemid 24310184)
142. Miyagawa S, Amagai M, Niizeki H, Yamashina Y, Kaneshige T, Nishikawa T, Shirai T, Inoko H. HLA-DRB1 polymorphisms and autoimmune responses to desmogleins in Japanese patients with Pemphigus. Tissue Antigens 1999;54: 333-340. (Pubitemid 29484274)
143. Hertl M, Karr RW, Amagai M, Katz SI. Heterogeneous MHCII restriction pattern of autoreactive desmoglein 3 specific T cell responses in Pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:388-392. (Pubitemid 28158655)
144. Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz LA. Development and characterization of desmoglein-3 specific T cells from patients with Pemphigus vulgaris. J Clin Invest 1997;99:3-40.
145. Riechers R, Grotzinger J, Hertl M. HLA class II restriction of autoreactive T cell responses in Pemphigus vulgaris: Review of the literature and potential applications for the development of a specific immunotherapy. Autoimmunity 1999;30: 183-196. (Pubitemid 29469243)
146. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with Pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 2003;170:635-642. (Pubitemid 36026193)
147. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T. Detection of antigen-specific B cells in patients with Pemphigus vulgaris by enzyme-linked immunospot assay: Requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000;114:88-94. (Pubitemid 30195978)
148. Tsunoda K, Ota T, Suzuki H, Ohyama M, Nagai T, Nishikawa T, Amagai M, Koyasu S. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both Tand B cells in experimental Pemphigus vulgaris. Eur J Immunol 2002;32:627-633. (Pubitemid 34257539)
149. Takahashi H, Amagai M, Nishikawa T, Fujii Y, Kawakami Y, Kuwana M. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine Pemphigus vulgaris. J Immunol 2008;181:1526-1535.
150. Aoki-Ota M, Kinoshita M, Ota T, Tsunoda K, Iwasaki T, Tanaka S, Koyasu S, Nishikawa T, Amagai M. Tolerance induction by the blockade of CD40/CD154 interaction in Pemphigus vulgaris mouse model. J Invest Dermatol 2006; 126:105-113. (Pubitemid 43336101)
151. Hertl M, Amagai M, Sundaram H, Stanley J, Ishii K, Katz SI. Recognition of desmoglein 3 by autoreactive T cells in Pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110:62-66. (Pubitemid 28086065)
152. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Boiko Y, Senyuk OF. Autoreactive cytotoxic T lymphocytes in Pemphigus and Pemphigoid. Autoimmunity 1989;3: 247-260. (Pubitemid 19205875)
153. Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grotzinger J, Schultz E, Hertl M. T cell recognition of desmoglein 3 peptides in patients with Pemphigus vulgaris and healthy individuals. J Immunol 2004;172:3883-3892. (Pubitemid 38337976)
154. Ahmed AR, Mohimen A, Yunis EJ, Mirza NM, Kumar V, Beutner EH, Alper CA. Linkage of Pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993;177:419-424. (Pubitemid 23117091)
155. Gebhard KL, Veldman CM,Wassmuth R, Schultz E, Schuler G, Hertl M. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with Pemphigus foliaceus and healthy individuals. Exp Dermatol 2005;14: 586-592. (Pubitemid 41030925)
156. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol 2008; 38:921-924.
157. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-190. (Pubitemid 30012989)
158. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006;16:115-123. (Pubitemid 43172060)
159. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006;116:1159-1166.
160. + CD25 high regulatory T cells are markedly decreased in blood of patients with Pemphigus vulgaris. Dermatology 2007;214:210-220. (Pubitemid 46457606)
161. Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with Pemphigus vulgaris. J Immunol 2004;172:6468-6475. (Pubitemid 38621257)
162. Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th17 cells in Pemphigus vulgaris and Pemphigus foliaceus. J Dermatol Sci 2009;53:228-231.
163. Sebaratnam DF, Martin LK, Rubin AI, Tran K, Pas HH, Marr PJ, Edmonds J, Murrell DF. Reversible relapse of Pemphigus foliaceus triggered by topical imiquimod suggests that Toll-like receptor 7 inhibitors may be useful treatments for Pemphigus. Clin Exp Dermatol 2011;36:91-93.
164. Shlomchik MJ. Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 2009;21:626-633.
165. Amagai M. Autoimmunity against desmosomal cadherins in Pemphigus. J Dermatol Sci 1999;20:92-102. (Pubitemid 29251586)
166. Udey MC, Stanley JR. Pemphigus-diseases of antidesmosomal autoimmunity. J Am Med Assoc 1999;282:572-576.
167. Karpati S, Amagai M, Prussick R, Cehrs K, Stanley JR. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol 1993; 122:409-415. (Pubitemid 23210467)
168. Iwatsuki K, Han GW, Fukuti R, Ohtsuka M, Kikuchi S, Akiba H, Kaneko F. Internalization of constitutive desmogleins with the subsequent induction of desmoglein 2 in Pemphigus lesions. Br J Dermatol 1999;140:35-43. (Pubitemid 29074528)
169. Bedane C, Prost C, Thomine E, Intrator L, Joly P, Caux F, Blecker M, Bernard P, Leboutet MJ, Tron F, Lauret P, Bonnetblanc JM, Dubertret L. Binding of autoantibodies is not restricted to desmosomes in Pemphigus vulgaris: Comparison of 14 cases of Pemphigus vulgaris and 10 cases of Pemphigus foliaceus studied by western immunoblot and immunoelectron microscopy. Arch Dermatol Res 1996;288: 343-352. (Pubitemid 26232084)
170. Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn D. Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction. J Clin Invest 2005;115: 3157-3165. (Pubitemid 41567580)
171. Muller EJ, Williamson L, Kolly C, Suter MM. Outside-in signaling through integrins and cadherins: A central mechanism to control epidermal growth and differentiation? J Invest Dermatol 2008;128:501-516. (Pubitemid 351252683)
172. Sharma P, Mao X, Payne AS. Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of Pemphigus. J Dermatol Sci 2007;48:1-14. (Pubitemid 47284801)
173. Bektas M, Runager K, Petersen JS, Rubenstein DS. Advances in Pemphigus research, signaling, and acantholysis. G Ital Dermatol Venereol 2010;145:675-688.
174. Berkowitz P, Hu P, Liu Z, Diaz LA, Enghild JJ, Chua MP, Rubenstein DS. Desmosome signaling: Inhibition of p38MAPK prevents Pemphigus vulgaris IgG induced cytoskeleton reorganization. J Biol Chem 2005;280: 23778-23784. (Pubitemid 40884862)
175. Rubenstein DS, Diaz LA. Pemphigus antibody induced phosphorylation of keratinocyte proteins. Autoimmunity 2006;39:577-586. (Pubitemid 44768926)
176. Lee HE, Berkowitz P, Jolly PS, Diaz LA, Chua MP, Rubenstein DS. Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in Pemphigus acantholysis. J Biol Chem 2009;284:12524-12532.
177. Jolly PS, Berkowitz P, Bektas M, Lee HE, Chua M, Diaz LA, Rubenstein DS. p38MAPK signaling and desmoglein-3 internalization are linked events in Pemphigus acantholysis. J Biol Chem 2010;285:8936-8941.
178. de Bruin A, Caldelari R, Williamson L, Suter MM, Hunziker T,Wyder M, Muller EJ. Plakoglobin-dependent disruption of the desmosomal plaque in Pemphigus vulgaris. Exp Dermatol 2007;16:468-475. (Pubitemid 46845389)
179. Muller EJ, Hunziker T, Suter MM. Keratin intermediate filament retraction is linked to plakoglobin-dependent signaling in Pemphigus vulgaris. J Am Acad Dermatol 2007;56:890-891, author reply 891-892. (Pubitemid 46578263)
180. Williamson L, Raess NA, Caldelari R, Zakher A, de Bruin A, Posthaus H, Bolli R, Hunziker T, Suter MM, Muller EJ. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J 2006;25:3298-3309. (Pubitemid 44141788)
181. Caldelari R, de Bruin A, Baumann D, Suter MM, Bierkamp C, Balmer V, Muller E. A central role for the armadillo protein plakoglobin in the autoimmune disease Pemphigus vulgaris. J Cell Biol 2001;153:823-834. (Pubitemid 34286113)
182. Calkins CC, Setzer SV, Jennings JM, Summers S, Tsunoda K, Amagai Mq, Kowalczyk AP. Desmoglein endocytosis and desmosome disassembly are coordinated responses to Pemphigus autoantibodies. J Biol Chem 2006;281: 7623-7634. (Pubitemid 43847533)
183. Delva E, Jennings JM, Calkins CC, Kottke MD, Faundez V, Kowalczyk AP. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin-and dynamin-independent mechanism. J Biol Chem 2008;283:18303-18313.
184. Jennings JM, Tucker DK, Kottke MD, Saito M, Delva E, Hanakawa Y, Amagai M, Kowalczyk AP. Desmosome disassembly in response to Pemphigus Vulgaris IgG occurs in distinct phases and can be reversed by expression of exogenous Dsg3. J Invest Dermatol 2011;131(3):706-718.
185. Tsunoda K, Ota T, Aoki M, Yamada T, Nagai T, Nakagawa T, Koyasu S, Nishikawa T, Amagai M. Induction of Pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003;170:2170-2178. (Pubitemid 36197441)
186. Kawasaki Y, Aoyama Y, Tsunoda K, Amagai M, Kitajima Y. Pathogenic monoclonal antibody against desmoglein 3 augments phosphorylation of desmoglein 3 and p38 MAPK in a human squamous carcinoma cell line. Autoimmunity 2006;39:587-590. (Pubitemid 44768927)
187. Nguyen B, Dusek RL, Beaudry VG, Marinkovich MP, Attardi LD. Loss of the desmosomal protein perp enhances the phenotypic effects of Pemphigus vulgaris autoantibodies. J Invest Dermatol 2009;129:1710-1718.
188. Sanchez-Carpintero I, Espana A, Pelacho B, Lopez Moratalla N, Rubenstein DS, Diaz LA, Lopez-Zabalza MJ. In vivo blockade of Pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol 2004;151:565-570. (Pubitemid 39330879)
189. Frusic-Zlotkin M, RaichenbergD,Wang X, David M, Michel B, Milner Y. Apoptotic mechanism in Pemphigus autoimmunoglobulins-induced acantholysis: Possible involvement of the EGF receptor. Autoimmunity 2006;39: 563-575. (Pubitemid 44768925)
190. Pretel M, España A, Marquina M, Pelacho B, Lopez-Picazo J, Lopez-Zabalza M. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of Pemphigus vulgaris. Exp Dermatol 2009;18:771-780.
191. Spindler V, Vielmuth F, Schmidt E, Rubenstein DS,Waschke J. Protective endogenous cyclic adenosine 50-monophosphate signaling triggered by Pemphigus autoantibodies. J Immunol 2010;185:6831-6838.
192. Seishima M, Iwasaki-Bessho Y, Itoh Y, Nozawa Y, Amagai M, Kitajima Y. Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in Pemphigus IgGinduced signal transduction. Arch Dermatol Res 1999;291: 606-613.
193. Cheng H, Kartenbeck J, Kabsch K, Mao X, Marques M, Alonso A. Stress kinase p38 mediates EGFR transactivation by hyperosmolar concentrations of sorbitol. J Cell Physiol 2002;192:234-243. (Pubitemid 34747792)
194. Kippenberger S, Bernd A, Loitsch S, Guschel M, Muller J, Bereiter-Hahn J, Kaufmann R. Signaling of mechanical stretch in human keratinocytes via MAP kinases. J Invest Dermatol 2000;114:408-412. (Pubitemid 30415324)
195. D'Alessandro M, Russell D, Morley SM, Davies AM, Lane EB. Keratin mutations of epidermolysis bullosa simplex alter the kinetics of stress response to osmotic shock. J Cell Sci 2002;115:4341-4351. (Pubitemid 35460704)
196. Schmidt E,Waschke J. Apoptosis in Pemphigus. Autoimmun Rev 2009;8:533-537.
197. Mao X, Sano Y, Park JM, Payne AS. p38 mitogen activated protein kinase (MAPK) activation is downstream of the loss of intercellular adhesion in Pemphigus vulgaris. J Biol Chem 2010;286(2):1283-1291.
198. Grando SA, PittelkowMR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: Physiological and clinical significance. J Invest Dermatol 2006;126: 1948-1965.
199. Calautti E, Grossi M, Mammucari C, Aoyama Y, Pirro M, Ono Y, Li J, Dotto GP. Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion. J Cell Biol 2002;156:137-148. (Pubitemid 34846942)
200. Serres M, Filhol O, Lickert H, Grangeasse C, Chambaz EM, Stappert J, Vincent C, SchmittD. The disruption of adherens junctions is associated with a decrease of E-cadherin phosphorylation by protein kinase CK2. Exp Cell Res 2000;257:255-264. (Pubitemid 30390476)
201. Moon HS, Choi EA, Park HY, Choi JY, Chung HW, Kim JI, Park WI. Expression and tyrosine phosphorylation of Ecadherin, beta-and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells. Gynecol Oncol 2001; 81:355-359. (Pubitemid 32494647)
202. Hu P, O'Keefe EJ, Rubenstein DS. Tyrosine phosphorylation of human keratinocyte beta-catenin and plakoglobin reversibly regulates their binding to E-cadherin and alpha-catenin. J Invest Dermatol 2001;117:1059-1067. (Pubitemid 34205898)
203. Lilien J, Balsamo J, Arregui C, Xu G. Turn-off, drop-out: Functional state switching of cadherins. Dev Dyn 2002;224: 18-29. (Pubitemid 34464929)
204. Volberg T, Zick Y, Dror R, Sabanay I, Gilon C, Levitzki A, Geiger B. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J 1992;11:1733-1742.
205. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993;120:757-766. (Pubitemid 23035144)
206. Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VE-cadherin prevents binding of p120-and betacatenin and maintains the cellular mesenchymal state. J Biol Chem 2005;280:31906-31912. (Pubitemid 41291941)
207. Yin T, Getsios S, Caldelari R, Godsel LM, Kowalczyk AP, Muller EJ, Green KJ. Mechanisms of plakoglobin-dependent adhesion: Desmosome-specific functions in assembly and regulation by epidermal growth factor receptor. J Biol Chem 2005;280:40355-40363. (Pubitemid 41779173)
208. Amar LS, Shabana AH, Oboeuf M, Martin N, Forest N. Involvement of desmoplakin phosphorylation in the regulation of desmosomes by protein kinase C, in HeLa cells. Cell Adhes Commun 1999;7:125-138.
209. Mueller H, Franke WW. Biochemical and immunological characterization of desmoplakins I and II, the major polypeptides of the desmosomal plaque. J Mol Biol 1983; 163:647-671. (Pubitemid 13114552)
210. Boyer B, Tucker GC, Valles AM, Franke WW, Thiery JP. Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 1989;109:1495-1509. (Pubitemid 19251206)
211. Pasdar M, Li Z, Chan H. Desmosome assembly and disassembly are regulated by reversible protein phosphorylation in cultured epithelial cells. Cell Motil Cytoskeleton 1995;30:108-121.
212. Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody. Pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol 1999;29: 2233-2240. (Pubitemid 29313098)
213. Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol 1999;112:67-71. (Pubitemid 29024708)
214. Nguyen VT, Arredondo J, Chernyavsky AI, Kitajima Y, Pittelkow M, Grando SA. Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem 2004;279:2135-2146. (Pubitemid 38084487)
215. Chernyavsky AI, Arredondo J, Piser T, Karlsson E, Grando SA. Differential coupling of M1 muscarinic and a7 nicotinic receptors to inhibition of Pemphigus acantholysis. J Biol Chem 2008;283:3401-3408.
216. Kitajima Y, Inoue S, Yaoita H. Effects of Pemphigus antibody on the organization of microtubules and keratin-intermediate filaments in cultured human keratinocytes. Br J Dermatol 1986;114:171-179. (Pubitemid 16131423)
217. Jinbu Y, Kitajima Y, Koto S, Akasaka Y, Yaoita H. Different effects of Pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes. J Dermatol Sci 1992;3:6-12.
218. Baroni A, Buommino E, Paoletti I, Orlando M, Ruocco E, Ruocco V. Pemphigus serum and captopril induce heat shock protein 70 and inducible nitric oxide synthase overexpression, triggering apoptosis in human keratinocytes. Br J Dermatol 2004;150:1070-1080. (Pubitemid 38932275)
219. Hashimoto K, Lever WF. An electron microscopic study on Pemphigus vulgaris of the mouth and the skin with special reference to the intercellular cement. J Invest Dermatol 1967; 48:540-552.
220. Hashimoto K, Lever WF. The intercellular cement in Pemphigus vulgaris, an electron microscopic study. Dermatologica 1967;135:27-34.
221. Sams WM, Jr, Gammon WR. Mechanism of lesion production in Pemphigus and Pemphigoid. J Am Acad Dermatol 1982;6:431-452.
222. Takahashi Y, Patel HP, Labib RS, Diaz LA, Anhalt GJ. Experimentally induced Pemphigus vulgaris in neonatal BALB/c mice: A time-course study of clinical, immunologic, ultrastructural, and cytochemical changes. J Invest Dermatol 1985;84:41-46. (Pubitemid 15186223)
223. Bystryn J-C, Grando SA. A novel explanation for acantholysis in Pemphigus vulgaris-the "basal cell shrinkage" hypothesis. J Am Acad Dermatol 2006;54:513-516. (Pubitemid 43243458)
224. Hotti A, Jarvinen K, Siivola P, Holtta E. Caspases and mitochondria in c-Myc-induced apoptosis: Identification of ATM as a new target of caspases. Oncogene 2000;19: 2354-2362. (Pubitemid 30307212)
225. Arredondo J, Chernyavsky AI, Karaouni A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. Am J Pathol 2005; 167:1531-1544. (Pubitemid 41713308)
226. Deb-Basu D, Aleem E, Kaldis P, Felsher DW. CDK2 is required by MYC to induce apoptosis. Cell Cycle 2006;5: 1342-1347. (Pubitemid 43894291)
227. Lanza A, Cirillo N, Rossiello R, Rienzo M, Cutillo L, Casamassimi A, de Nigris F, Schiano C, Rossiello L, Femiano F, Gombos F, Napoli C. Evidence of key role of Cdk2 overexpression in Pemphigus vulgaris. J Biol Chem 2008;283:8736-8745.
228. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-2746. (Pubitemid 38114263)
229. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009;16:1017-1027.
230. Gniadecki R, Jemec GB, Thomsen BM, Hansen M. Relationship between keratinocyte adhesion and death: Anoikis in acantholytic diseases. Arch Dermatol Res 1998; 290:528-532. (Pubitemid 28502230)
231. Puviani M, Marconi A, Cozzani E, Pincelli C. Fas ligand in Pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8. J Invest Dermatol 2003;120: 164-167. (Pubitemid 36120986)
232. Pelacho B, Natal C, Espana A, Sanchez-Carpintero I, Iraburu MJ, Lopez-Zabalza MJ. Pemphigus vulgaris autoantibodies induce apoptosis in HaCaT keratinocytes. FEBS Lett 2004;566:6-10. (Pubitemid 38625923)
233. Milner Y, Metezeau P, Kiefer H, Finemesser M, Bregegere F, Zlotkin M, Wang X, Michel B. Pemphigus an autoimmune disease of the skin: Cell-cell separation versus membrane signaling and apoptosis in acantholysis. In: Shoenfeld Y, editor. The decade of autoimmunity. 4th ed. Elsevier Science B.V. 1999. p 606-615.
234. Frusic-Zlotkin M, Pergamentz R, Michel B, David M, Mimouni D, Bregegere F, Milner Y. The interaction of Pemphigus autoimmunoglobulins with epidermal cells: Activation of the fas apoptotic pathway and the use of caspase activity for pathogenicity tests of Pemphigus patients. Ann N Y Acad Sci 2005;1050:371-379. (Pubitemid 41129456)
235. Pacheco-Tovar MG, Avalos-Diaz E, Vega-Memije E, Bollain-y-Goytia JJ, Lopez-Robles E, Hojyo-Tomoka MT, Dominguez-Soto L, Herrera-Esparza R. The final destiny of acantholytic cells in Pemphigus is Fas mediated. J Eur Acad Dermatol Venereol 2009;23:697-701.
236. Lotti R, Shu E, Truzzi F, Palazzo E, Marconi A, Kitajima Y, Pincelli C. Apoptosis precedes desmoglein cleavage and keratinocyte dissociation in Pemphigus: Anti-Fas Ligand neutralizing antibodies prevent acantholysis both in vitro and in vivo. J Invest Dermatol 2009;129(Suppl):S14, (Abstr. #80).
237. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, Wang B, Sauder DN. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in Pemphigus vulgaris: Interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000;114:71-77. (Pubitemid 30195975)
238. Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, Hojyo-Tomoka R, Villalobos S, Fraire L, Domiguez-Soto L, Herrera-Esparza R. TNFalpha and IL-6 are mediators in the blistering process of Pemphigus. Int J Dermatol 2001;40: 185-188. (Pubitemid 32586277)
239. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, Ferraro C, Ameglio F. Cytokines in the sera of patients with Pemphigus vulgaris: Interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997;8:383-387. (Pubitemid 28031326)
240. Ameglio F, D'Auria L, Cordiali-Fei P, Trento E, D'Agosto G, Mastroianni A, Giannetti A, Giacalone B. Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with Pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents 1999;13:220-224.
241. Orlov MD, Chernyavsky AI, Arredondo J, Grando SA. Synergistic actions of Pemphigus vulgaris IgG. Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis. Autoimmunity 2006;39: 557-562. (Pubitemid 44768924)
242. Grando SA. Decompensation in proteinase-inhibitor system and application of proteinase inhibitors in Pemphigus and Pemphigoid. J Dermatol Sci 1992;4:95-97. (Pubitemid 23029544)
243. Grando SA, Drannik GN, Glukhenky BT, Kostromin AP, Romanenko AB, Chayun OA, Chernyavsky AI. Clinical and laboratory evaluation of hemocarboadsorption in autoimmune bullous dermatoses. Int J Artif Organs 1990;3: 181-188. (Pubitemid 20293285)
244. Keskin DB, Stern JN, Fridkis-Hareli M, Ahmed AR. Cytokine profiles in Pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine 2008;41: 315-321.
245. Cirillo N, Lanza M, Femiano F, Gaeta GM, De Rosa A, Gombos F, Lanza A. If Pemphigus vulgaris IgG are the cause of acantholysis, new IgG-independent mechanisms are the concause. J Cell Physiol 2007;212:563-567. (Pubitemid 47267524)
246. Wang X, Bregegere F, Frusic-Zlotkin M, Feinmesser M, Michel B, Milner Y. Possible apoptotic mechanism in epidermal cell acantholysis induced by Pemphigus vulgaris autoimmunoglobulins. Apoptosis 2004;9:131-143. (Pubitemid 38987590)
247. Wang X, Bregegere F, Soroka Y, Frusic-Zlotkin M, Milner Y. Replicative senescence enhances apoptosis induced by Pemphigus autoimmune antibodies in human keratinocytes. FEBS Lett 2004;567:281-286. (Pubitemid 38748406)
248. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI. Cytotoxic proteases in blister fluid of Pemphigus and Pemphigoid patients. Int J Tissue React 1989;11:195-201. (Pubitemid 20123545)
249. Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with Pemphigus vulgaris and bullous Pemphigoid. Arch Dermatol 1989;125:925-930. (Pubitemid 19174689)
250. Rico MJ, Benning C,Weingart ES, Streilein RD, Hall RP, III. Characterization of skin cytokines in bullous Pemphigoid and Pemphigus vulgaris. Br J Dermatol 1999;140:1079-1086. (Pubitemid 29284580)
251. Berkowitz P, Hu P, Warren S, Liu Z, Diaz LA, Rubenstein DS. p38MAPK inhibition prevents disease in Pemphigus vulgaris mice. Proc Natl Acad Sci USA 2006;103: 12855-12860.
252. Lanza A, Cirillo N. Caspase-dependent cleavage of desmoglein 1 depends on the apoptotic stimulus. Br J Dermatol 2007;156:400-402. (Pubitemid 46095988)
253. Cirillo N, Lanza M, De Rosa A, Cammarota M, La Gatta A, Gombos F, Lanza A. The most widespread desmosomal cadherin, desmoglein 2, is a novel target of caspase 3-mediated apoptotic machinery. J Cell Biochem 2008;103: 598-606. (Pubitemid 351171930)
254. Holubar K, Fellner MJ. Pemphigus and related diseases. In: Rook A, Parish LC, Beare JM, editors. Practical management of the dermatologic patient. Philadelphia: Lippincott Company; 1986. p 153-155.
255. Muller S, Stanley JR. Pemphigus: Pemphigus vulgaris and Pemphigus foliaceus. In: Wojnarowska F, Briggaman RA, editors. Management of blistering diseases. London: Chapman and Hall Medical; 1990. p 43-61.
256. Lever WF. Pemphigus and pemphigoid. Charles C. Thomas, Springfield; 1965.
257. Lever WF, Schaumburg-Lever G. Treatment of Pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 1984;120:44-47.
258. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP. Consensus statement on definitions of disease, end points, and therapeutic response for Pemphigus. J Am Acad Dermatol 2008;58:1043-1046.
259. Grando SA, Grando AA, Glukhenky BT, Doguzov V, Nguyen VT, Holubar K. History and clinical significance of mechanical symptoms in blistering dermatoses: A reappraisal. J Am Acad Dermatol 2003;48:86-92. (Pubitemid 36091539)
260. Talbott JH, Lever WF, Consolazio WV. Metabolic studies on patients with Pemphigus. J Invest Dermatol 1940;3:31.
261. Thorn GW, Forsham PH, Frawley TF, Hill SR, Jr, Roche M, Staehelin D, Wilson DL. Clinical usefulness of ACTH and cortisone. New Eng J Med 1950;242:783, 824, 865.
262. Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009;145:1005-1008.
263. Alexandroff AB, Harman KE. Blistering skin disorders: An evidence-based update. Conference report. Br J Dermatol 2009;160:502-504.
264. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CH, Saag KG. Populationbased assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-426. (Pubitemid 43887028)
265. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-137. (Pubitemid 351339883)
266. Lever WF, Goldberg HS. Treatment of Pemphigus vulgaris with methotrexate. Arch Dermatol 1969;100:70-78.
267. Wolff K, Schreiner E. Immunosuppressive therapy of Pemphigus vulgaris. Preliminary results of azathioprine (Imuran) treatment (in German). Arch Klin Exp Dermatol 1969;235:63-77.
268. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of Pemphigus vulgaris and bullous Pemphigoid. Arch Dermatol 1982;106:657-661.
269. Piamphongsant T, Ophaswongse S. Treatment of Pemphigus. Int J Dermatol 1991;30:139-146.
270. Enk AH, Knop J. Treatment of Pemphigus vulgaris with mycophenolate mofetil. Lancet 1997;350:494. (Pubitemid 27343313)
271. Mashkilleyson NA. Heparin action in Pemphigus vulgaris: Clinical and immunologic studies. Acta Derm Venereol 1985;65:545-547. (Pubitemid 16204666)
272. Balda BR, Rosenzweig D. Cyclosporin A in the treatment of Pemphigus foliaceus and Pemphigus erythematosus (In German). Hautarzt 1986;37:454-457. (Pubitemid 16039208)
273. Knobler RM. Photopheresis-extracorporeal irradiation of 8-MOP containing blood-a new therapeutic modality. Blut 1987;54:247-250. (Pubitemid 17056441)
274. Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gamma-globulin in Pemphigus. J Am Acad Dermatol 1990;22:326.
275. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening Pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002;47:785-788. (Pubitemid 35239347)
276. Renkl A, Mockenhaupt M, Technau K, Herouy Y, Norgauer J. A novel therapeutic option in Pemphigus vulgaris: Humanized monoclonal anti-CD25 antibody. Br J Dermatol 2004;150:1220-1222. (Pubitemid 38932304)
277. Penneys NS, Eaglstein WH, Indgin S, Frost P. Gold sodium thiomalate treatment of Pemphigus. Arch Dermatol 1973; 108:56-60.
278. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of Pemphigus vulgaris. Dermatologica 1978;156:120-123. (Pubitemid 8251426)
279. Grando SA. Combined immunosuppressive therapy of autoimmune bullous dermatoses (In Russian). Sov Med 1988;2:113-115.
280. Chaffins ML, Collison D, Fivenson DP. Treatment of Pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 cases. J Am Acad Dermatol 1993; 28:998-1000. (Pubitemid 23160654)
281. Sawai T, Kitazawa K, Danno K, Sugie T, Machizuki T, Sugiura H, Uehara M. Pemphigus vegetans with oesophageal involvement: Successful treatment with minocycline and nicotinamide. Br J Dermatol 1995;132:668-670.
282. Miyamoto H, Takahashi I. Successful treatment of Pemphigus vulgaris with prednisolone and tranilast. Acta Derm Venereol 1997;77:87-88. (Pubitemid 27067310)
283. Cunha PR, de Oliveira JR, Salles MR, Jamora J, Bystryn JC. Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy. Int J Dermatol 2004;43:682-684. (Pubitemid 39276299)
284. Ruocco V, Rossi A, Argenziano G, Aatarita C, Alviggi L, Farzati B, Papaleo G. Pathogenicity of the intercellular antibodies of Pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol 1978;98: 237-241. (Pubitemid 8287268)
285. Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of Pemphigus vulgaris. Br J Dermatol 1978; 98:243. (Pubitemid 8287269)
286. Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M, Mansouri Taleghoni B, Brocker EB, Zillikens D. Protein A immunoadsorption: A novel and effective adjuvant treatment of severe Pemphigus. Br J Dermatol 2003;148: 1222-1229. (Pubitemid 36819223)
287. Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest 2000;38:498-509.
288. + lymphocytes by inhibiting IL-12 production. J Immunol 1998;160:2231-2237. (Pubitemid 28119903)
289. Mainali ES, Kikuchi T, Tew JG. Dexamethasone inhibits maturation and alters function of monocyte-derived dendritic cells from cord blood. Pediatr Res 2005;58:125-131. (Pubitemid 40967442)
290. Miyaura H, Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol 2002;168:1087-1094. (Pubitemid 34094472)
291. Swanson DL, Dahl MV. Methylprednisolone inhibits Pemphigus acantholysis in skin cultures. J Invest Dermatol 1983;81:258-260. (Pubitemid 13045265)
292. Jeffes EW, Kaplan RP, Ahmed AR. Acantholysis produced in vitro with Pemphigus serum: Hydrocortisone inhibits acantholysis, while dapsone and 6-mercaptopurine do not inhibit acantholysis. J Clin Lab Immunol 1984;4:359-363. (Pubitemid 14013170)
293. Fine JD, Appell ML, Green LK, Sams WM, Jr. Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol 1988;124:236-239. (Pubitemid 18054506)
294. Werth VP. Treatment of Pemphigus vulgaris with brief, highdose intravenous glucocorticoids. Arch Dermatol 1996;132: 1435-1439. (Pubitemid 26424542)
295. Roujeau JC. Pulse glucocorticoid therapy. The "big shot" revisited. Arch Dermatol 1996;132:1499-1502.
296. Chryssomallis F, Dimitriades A, Chaidemenos GC, Panagiotides D, Karakatsanis G. Steroid-pulse therapy in Pemphigus vulgaris long term follow-up. Int J Dermatol 1995;34: 438-442.
297. Saxon A, Stevens RH, Ramer SJ, Clements PJ, Yu DT. Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in in vitro immunoglobulin synthesis. J Clin Invest 1978;61:922-930. (Pubitemid 8321070)
298. Aksu D, Peksari Y, Arica IE, Gurgey E. Assessing the autoantibody levels in relation to disease severity and therapy response in Pemphigus patients. Indian J Dermatol 2010;55: 342-347.
299. Dumas V, Roujeau JC, Wolkenstein P, Revuz J, Cosnes A. The treatment of mild Pemphigus vulgaris and Pemphigus foliaceus with a topical corticosteroid. Br J Dermatol 1999; 140:1127-1129. (Pubitemid 29284588)
300. Dobrev H, Popova L, Vlashev D. Proteinase inhibitors and Pemphigus vulgaris. An in vitro and in vivo study. Arch Derm Res 1996;288:648-655. (Pubitemid 26377459)
301. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant Pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004;74:245-247. (Pubitemid 39462890)
302. Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant Pemphigus vulgaris and Pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005;141:680-682. (Pubitemid 41001066)
303. Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of Pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009;8:940-943.
304. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe Pemphigus vulgaris. Br J Dermatol 2005;153:222-223. (Pubitemid 41044564)
305. Jacobi A, Shuler G, Hertl M. Rapid control of therapyrefractory Pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005;153:448-449. (Pubitemid 41228454)
306. Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA Pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 2005;53: 541-543. (Pubitemid 41196003)
307. Schultz HY, Diaz LA, Sirois DA, Werth VP, Grando SA. Generating Consensus Research Goals and Treatment Strategies for Pemphigus and Pemphigoid: The 2010 JC Bystryn Pemphigus and Pemphigoid Meeting. J Invest Dermatol 2011;131(7):1395-1399.
308. Alpsoy E, Yilmaz E, Basaran E, Yazar S, Cetin L. Is the combination of tetracycline and nicotinamide therapy alone effective in Pemphigus? Arch Dermatol 1995;131: 1339-1340.
309. Hausermann P, Gutersohn T, Beltraminelli H, Schiller P, Buchner SA, Rufli T. [Oral Pemphigus vulgaris. Successful treatment with minocycline and nicotinamide]. Hautarzt 2002;53:813-815. (Pubitemid 36069814)
310. Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of Pemphigus vulgaris. Dermatol Ther 2010;23:308-311.
311. Romanenko AV. The action of nicotinamide on neuromuscular transmission. Fiziologicheskii Zhurnal (Kiev) 1987;33: 51-56.
312. Koeppen A, Klein J, Erb C, Loeffelholz K. Acetylcholine release and choline availability in rat hippocampus: Effects of exogenous choline and nicotinamide. J Pharmacol Exp Ther 1997;282:1139-1145. (Pubitemid 27408288)
313. Stoytcheva M, Zlatev R. Bioelectrocatalytical studies of the effect of some pharmaceuticals on the acetylcholinesterase activity. Electroanalysis 1996;8:676-679. (Pubitemid 126419573)
314. Mehta JN, Martin AG. A case of Pemphigus vulgaris improved by cigarette smoking. Arch Dermatol 2000;136: 15-17. (Pubitemid 30038791)
315. Brenner S, Tur E, Shapiro J, Ruocco V, D'Avino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Brezoev P, Barnadas MA, Gonzalez MJ, Anhalt G, Nousari H, Silva MR, Pinto KT, Miranda MF. Pemphigus vulgaris: Environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001;40:562-569. (Pubitemid 33081042)
316. Sullivan TP, Elgart GW, Kirsner RS. Pemphigus and smoking. Int J Dermatol 2002;41:528-530. (Pubitemid 35021502)
317. Valikhani M, Kavusi S, Chams-Davatchi C, Daneshpazhooh M, Barzegari M, Ghiasi M, Abedini R. Pemphigus and associated environmental factors: A case-control study. Clin Exp Dermatol 2007;32:256-260. (Pubitemid 46495810)
318. Valikhani M, Kavusi S, Chams-Davatchi C, Hallaji Z, Esmaili N, Ghandi N, Farahani F, Lajevardi V. Impact of smoking on Pemphigus. Int J Dermatol 2008;47:567-570. (Pubitemid 351676495)
319. Morimoto N, Takemoto S, Kawazoe T, Suzuki S. Nicotine at a low concentration promotes wound healing. J Surg Res 2008;145:199-204. (Pubitemid 351329319)
320. Arredondo J, Omelchenko DM, Chernyavsky AI, Qian J, Skok M, Grando SA. Functional role of the nicotinic arm of the acetylcholine regulatory axis in human B-cell lines. J Exp Pharmacol 2009;1:1-7.
321. Chernyavsky AI, Arredondo J, Galitovskiy V, Qian J, Grando SA. Structure and function of the nicotinic arm of acetylcholine regulatory axis in human leukemic T cells. Int J Immunopathol Pharmacol 2009;22:461-472.
322. Chernyavsky AI, Arredondo J, Skok M, Grando SA. Auto/ paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors. Int Immunopharmacol 2010;10:308-315.
323. + regulatory T cells in mice in vitro. J Pharmacol Exp Ther 2010;335: 553-561.
324. Qian J, Galitovskiy V, Chernyavsky AI, Marchenko S, Grando SA. Plasticity of the murine spleen T-cell cholinergic receptors and their role in in vitro differentiation of naive CD4 T cells toward the Th1. Th2 and Th17 lineages. Genes Immun 2011;12:222-230.
325. Akaike A, Ikeda SR, Brookes N, Pascuzzo GJ, Rickett DL, Albuquerque EX. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptorionic channel complex. II. Patch clamp studies. Mol Pharmacol 1984;25:102-112. (Pubitemid 14223260)
326. Taylor P. Anticholinesterase agents. In: Gilman AG, Goodman LS, Rall TW, Murad F, editors. Goodman and Gilman's pharmacological basis of therapeutics. New York: Macmillan; 1985. p 110-127.
327. Grando SA, Kist DA, QiM, Dahl MV. Human keratinocytes synthesize, secrete and degrade acetylcholine. J Invest Dermatol 1993;101:32-36. (Pubitemid 23213008)
328. Lanza A, Stellavato A, Heulfe I, Landi C, Gombos F, Cirillo N. Serum of patients with oral Pemphigus vulgaris impairs keratinocyte wound repair in vitro: A time-lapse study on the efficacy of methylprednisolone and pyridostigmine bromide. Oral Dis 2009;15:478-483.
329. Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004; 140:327-334. (Pubitemid 38332484)
330. Grando SA. New approaches to the treatment of Pemphigus. J Invest Dermatol Symp Proc 2004;9:84-91. (Pubitemid 38096204)
331. Nait K, Morioka S, Nakajima S, Ogawa H. Proteinase inhibitors block formation of Pemphigus acantholysis in experimental models of neonatal mice and skin explants: Effects of synthetic and plasma proteinase inhibitors on Pemphigus acantholysis. J Invest Dermatol 1989;93: 173-177. (Pubitemid 19183334)
332. Iraji F, Yoosefi A. Healing effect of Pilocarpine gel 4% on skin lesions of Pemphigus vulgaris. Int J Dermatol 2006;45: 743-746. (Pubitemid 44056680)
333. Kebabian JW, Neumeyer JL, editors. The RBI handbook of receptor classification. Natick: Research Biochemicals International; 1994.
334. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of Pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355: 1772-1779. (Pubitemid 44631360)
335. Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007;22(Suppl 8):viii61-viii65.
336. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S. (Pubitemid 36547910)
337. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73:1565-1572. (Pubitemid 34568667)
338. Liu L, Chen L, Chung J, Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008;27:4998-5010.
339. Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in Pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003;2: 278-283. (Pubitemid 37083495)
340. Schumann H, Baetge J, Tasanen K,Wojnarowska F, Schacke H, ZillikensD, Bruckner-Tuderman L. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000;156: 685-695. (Pubitemid 30643823)
341. Simpson A, Levin D, Kazerounian S, Uitto J, Aho S, Mahoney MG. Desmoglein 2 is a new antigenic target of Pemphigus autoantibodies (abstr. #23). J Invest Dermatol 2001;117:393.
342. Kljuic A, Bazzi H, Sundberg JP,Martinez-Mir A, O'Shaughnessy R, Mahoney MG, Levy M, Montagutelli X, AhmadW, Aita VM, Gordon D, Uitto J, Whiting D, Ott J, Fischer S, Gilliam TC, Jahoda CA, Morris RJ, Panteleyev AA, Nguyen VT, Christiano AM. Desmoglein 4 in hair follicle differentiation and epidermal adhesion. Evidence from inherited hypotrichosis and acquired Pemphigus vulgaris. Cell 2003; 113:249-260. (Pubitemid 36514975)
343. Kim SC, Chung YL, Kim J, Cho NJ, Amagai M. Pemphigus vulgaris with autoantibodies to desmoplakin. Br J Dermatol 2001;145:838-840.
344. Evangelista F, Dasher DA, Diaz LA, Prisayanh PS, Li N. E-cadherin is an additional immunological target for Pemphigus autoantibodies. J Invest Dermatol 2008;128: 1710-1718. (Pubitemid 351847386)
345. Korman NJ, Eyre RW, Klaus-Kovtun V, Stanley JR. Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of Pemphigus foliaceus and Pemphigus vulgaris. N Engl J Med 1989;321:631-635. (Pubitemid 19221306)
346. Lambert J, Bracke S, van Roy F, Pas HH, Bonne S, De Schepper S. Serum plakophilin-3 autoreactivity in paraneoplastic Pemphigus. Br J Dermatol 2010;163:630-632.
347. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-Fc1RIa autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998;101:243-251. (Pubitemid 28058924)
348. Grando SA. Pemphigus in the XXI Century: New life to an old story. Autoimmunity 2006;39:521-530. (Pubitemid 46401640)
349. Pitoia F, Moncet D, Glorio R, Graciela Diaz A, Rodriguez Costa G, Carbia S, Cabrera H, Niepomniszcze H. Prevalence of thyroid autoimmunity in patients with Pemphigus vulgaris. Medicina (B Aires) 2005;65:307-310. (Pubitemid 41387521)
350. Rickman L, Simrak D, Stevens HP, Hunt DM, King IA, Bryant SP, Eady RA, Leigh IM, Arnemann J, Magee AI, Kelsell DP, Buxton RS. N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Hum Mol Genet 1999;8: 971-976. (Pubitemid 29250884)
351. Baroni A, Buommino E, Ruocco E, Petrazzuolo M, De Filippis A, Satriano RA, Ruocco V, et al. Captopril modulates acetylcholinesterase in human keratinocytes. Arch Dermatol Res 2011;303:491-497.